Market research
AUPH Aurinia Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- 7.3
- Analyst target
- 17.8571
- Dividend yield
- Not available
- Beta
- 1.4
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA05156V1022
- Market cap
- 2B
- P/E ratio
- 7.3
- Analyst target
- 17.8571
- Dividend yield
- Not available
- Beta
- 1.4
About
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the AUPH discussion.
5 years, 4 months ago
Aurinia Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 12.3% below its 200 day moving average.
From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 30.7.
Aurinia Pharmaceuticals Inc's total revenue rose by 172417.2% to $50M since the same quarter in the previous year.
Its net income has increased by 70.5% to $-23M since the same quarter in the previous year.
Finally, its free cash flow grew by 103.9% to $988K since the same quarter in the previous year.
Based on the above factors, Aurinia Pharmaceuticals Inc gets an overall score of 4/5.